PLATFORM PATENT (FILM PATENT)
Nicoccino is licensing the platform patent from Uppsala Gruppen Medical AB.
The Platform patent aims to protect the production of a strip that dissolves in the mouth when attached to a mucous membrane, releasing an active substance into the bloodstream via the membrane in the process.
The patent is exclusive and licensed to the Company during the patent’s period of validity for products containing nicotine. This is a royalty free lifetime license agreement and The Company will cover any costs related to retaining the patent.
The Patent Application (PCT-application) is so far approved and protected by twelve countries (Sweden, USA, China, Russia, Japan, Australia, New Zealand, South Africa, Israel, South Korea, Mexico and Canada) until 2026. The patent application is pending in four additional countries as well as the EU.
The Nicotine patent is owned by Nicoccino.
The Nicotine patent aims to protect the capability of quickly supplying nicotine via mucous membranes in the mouth using a product that can be stored in room temperature without breaking down the nicotine.
Singapore was the first market to approve the Company's own nicotine patent (March 2016) which enhances and extends the protection of the platform until 2033. New Zealand has as the second country (September 2016) accepted the Company’s nicotine patent. The patent will be sealed and approved after a three months opposition period where interest party can file an opposition.
The Patent application is filed in additionally fourteen countries as well as the EU.
Nicoccino™ is a trademark owned by Nicoccino AB, with approval in all EU member states. Logotype, symbols and graphic design was approved in October 2014. Nicoccino™ has also been approved in Canada, China, Monaco, Norway, South Korea, Turkey and the United States. Approval for Israel, Kazakhstan, Russia and Switzerland are pending.